Ionis Pharmaceuticals, Inc. <IONS.O>: BMO initiates coverage with market perform rating; price target $60
IONS•Related News
Merck, Moderna Say Melanoma Skin Cancer Treatment Meets Main Goal In Late-Stage Trial
MRK•
Gold Fields agrees to C$76.96 million Founders Metals share subscription for 19.9% stake
GFI•
The little reactors that could? How SMRs became nuclear's best bet: Maguire
XLU•
BioMarin Pharmaceutical Inc. <BMRN.O>: BMO initiates coverage with outperform rating; price target $98
BMRN•
Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
NSRX•